Donepezil for the treatment of psychosis in dementia with Lewy bodies
โ Scribed by Emma Fergusson; Robert Howard
- Publisher
- John Wiley and Sons
- Year
- 2000
- Tongue
- English
- Weight
- 49 KB
- Volume
- 15
- Category
- Article
- ISSN
- 0885-6230
No coin nor oath required. For personal study only.
๐ SIMILAR VOLUMES
The objective of this study was to assess the tolerability and efficacy of rivastigmine in a group of patients with probable dementia with Lewy bodies (DLB), using an open label study. Open label treatment was with rivastigmine up to maximum tolerated dose (mean 9.6 mg daily, range 3-12 mg). Eleven
In several retrospective post-mortem studies, patients meeting clinical criteria for Alzheimer's disease (AD) who gained the greatest cognitive beneยฎt from treatment with an acetylcholinesterase (AChE) inhibitor were found to have neocortical Lewy bodies accompanying classical AD neuropathology. Thi
The majority of information available on the prognosis of dementia with Lewy bodies (DLB) is based on retrospective data from autopsy series, which are subject to selection bias due to the speciยฎc reasons patients are referred for postmortem studies. The earlier studies comparing DLB patients with p